Med-X (MXRX) EBITDA Margin %: -297.33% (As of Dec. 2022)


What is Med-X EBITDA Margin %?

Med-X MXRX EBITDA Margin % is -297.33% as of Dec. 2022.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Med-X's EBITDA for the six months ended in Dec. 2022 was $-2.89 Mil. Med-X's Revenue for the six months ended in Dec. 2022 was $0.97 Mil. Therefore, Med-X's EBITDA margin for the quarter that ended in Dec. 2022 was -297.33%.

Med-X  (NAS:MXRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Med-X EBITDA Margin % Related Terms

Med-X EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Med-X's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med-X EBITDA Margin % Chart

Med-X Annual Data
Trend Dec20 Dec21 Dec22
EBITDA Margin %
-330.56 -519.60 -393.58

Med-X Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22
EBITDA Margin % 0.00 -415.45 -618.53 -499.77 -297.33

MXRX vs : EBITDA Margin % Comparison

For the Household & Personal Products subindustry, Med-X's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Med-X EBITDA Margin % vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Med-X's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Med-X's EBITDA Margin % falls into.


Med-X EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Med-X's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-7.293/1.853
=-393.58 %

Med-X's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-2.89/0.972
=-297.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -297.33% mean?
Med-X (MXRX) has a EBITDA Margin % of -297.33% as of Dec. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Med-X and its competitors.
Is Med-X's EBITDA Margin % too high?
Med-X's current EBITDA Margin % is -297.33%.
How does Med-X's EBITDA Margin % compare to ?
Med-X's EBITDA Margin % of -297.33% can be compared against companies in the Consumer Packaged Goods industry. The industry median EBITDA Margin % is 8.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Med-X and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med-X's current EBITDA Margin % is -297.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med-X stock overvalued right now?
Med-X (MXRX) has a current EBITDA Margin % of -297.33%. The current EBITDA Margin % is -297.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Med-X (MXRX), the current EBITDA Margin % is -297.33% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Med-X Business Description

Comparable Companies
Address 8236 Remmet Avenue, Canoga Park, CA, USA, 91304
Med-X Inc is engaged in the business of product development, distribution, and marketing of products, which currently consist of Nature-Cide, Thermal-Aid, and Malibu Brands. Nature-Cide products include natural essential oil blends of indoor and outdoor pesticide/insecticide/repellent developed for multiple industries, including professional pest control, turf care, janitorial, hospitality, transportation, and agriculture. Thermal-Aid, Thermal-Aid Zoo, and the Thermal-Aid Headache Relief System are natural heating/cooling pain and physical therapy products for painful ailments affecting adults, children, and animals. Nature-Cide. Malibu Brands has only one product available, an all-natural essential oil pain management cream.